These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 33794090)

  • 21. Synthetic Oligosaccharide-Based Vaccines Protect Mice from
    Broecker F; Wegner E; Seco BMS; Kaplonek P; Bräutigam M; Ensser A; Pfister F; Daniel C; Martin CE; Mattner J; Seeberger PH
    ACS Chem Biol; 2019 Dec; 14(12):2720-2728. PubMed ID: 31692324
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glycan Microarrays Containing Synthetic Streptococcus pneumoniae CPS Fragments and Their Application to Vaccine Development.
    Kaplonek P; Seeberger PH
    Methods Mol Biol; 2022; 2460():193-206. PubMed ID: 34972938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical studies on new proteins as carrier for glycoconjugate vaccines.
    Tontini M; Romano MR; Proietti D; Balducci E; Micoli F; Balocchi C; Santini L; Masignani V; Berti F; Costantino P
    Vaccine; 2016 Jul; 34(35):4235-4242. PubMed ID: 27317455
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-Group B Streptococcus Glycan-Conjugate Vaccines Using Pilus Protein GBS80 As Carrier and Antigen: Comparing Lysine and Tyrosine-directed Conjugation.
    Nilo A; Morelli L; Passalacqua I; Brogioni B; Allan M; Carboni F; Pezzicoli A; Zerbini F; Maione D; Fabbrini M; Romano MR; Hu QY; Margarit I; Berti F; Adamo R
    ACS Chem Biol; 2015 Jul; 10(7):1737-46. PubMed ID: 25906283
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification and Design of Synthetic B Cell Epitopes for Carbohydrate-Based Vaccines.
    Broecker F; Seeberger PH
    Methods Enzymol; 2017; 597():311-334. PubMed ID: 28935109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expanding the Scope of Ugi Multicomponent Bioconjugation to Produce Pneumococcal Multivalent Glycoconjugates as Vaccine Candidates.
    Humpierre AR; Zanuy A; Saenz M; Garrido R; Vasco AV; Pérez-Nicado R; Soroa-Milán Y; Santana-Mederos D; Westermann B; Vérez-Bencomo V; Méndez Y; García-Rivera D; Rivera DG
    Bioconjug Chem; 2020 Sep; 31(9):2231-2240. PubMed ID: 32809806
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expanding polysaccharide-protein coupling of glycoconjugate vaccines.
    Berti F
    J Biol Chem; 2022 Mar; 298(3):101755. PubMed ID: 35202656
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of the Minimal Glycotope of Streptococcus pneumoniae 7F Capsular Polysaccharide using Synthetic Oligosaccharides.
    Ménová P; Sella M; Sellrie K; Pereira CL; Seeberger PH
    Chemistry; 2018 Mar; 24(16):4181-4187. PubMed ID: 29333751
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Carbohydrate-Based Vaccines: An Overview.
    Hütter J; Lepenies B
    Methods Mol Biol; 2015; 1331():1-10. PubMed ID: 26169731
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccines based on the cell surface carbohydrates of pathogenic bacteria.
    Jones C
    An Acad Bras Cienc; 2005 Jun; 77(2):293-324. PubMed ID: 15895165
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel strategies for development of next-generation glycoconjugate vaccines.
    Avci FY
    Curr Top Med Chem; 2013; 13(20):2535-40. PubMed ID: 24066893
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure-based glycoconjugate vaccine design: The example of Group B Streptococcus type III capsular polysaccharide.
    Carboni F; Adamo R
    Drug Discov Today Technol; 2020 Dec; 35-36():23-33. PubMed ID: 33388125
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A new vaccine concept: polysaccharide conjugate vaccines].
    Moreau M
    Ann Pharm Fr; 1999 May; 57(3):223-31. PubMed ID: 10427857
    [TBL] [Abstract][Full Text] [Related]  

  • 34. O-phthalaldehyde based quantification of polysaccharide modification in conjugate vaccines.
    Rajendar B; Reddy MVNJ; Suresh CNV; Rao GS; Matur RV
    J Pharm Biomed Anal; 2024 Apr; 241():115995. PubMed ID: 38309096
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [CONTEMPORARY CONCEPTION OF IMMUNE RESPONSE ACTIVATION MECHA- NISM BY CONJUGATED POLYSACCHARIDE VACCINES].
    Kolesnikov AV; Kozyr AV; Schemyakin IG; Dyatlov IA
    Zh Mikrobiol Epidemiol Immunobiol; 2015; (3):97-106. PubMed ID: 26259279
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent developments in synthetic oligosaccharide-based bacterial vaccines.
    Pozsgay V
    Curr Top Med Chem; 2008; 8(2):126-40. PubMed ID: 18289082
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gold Nanoparticles as Carriers for Synthetic Glycoconjugate Vaccines.
    Chiodo F; Marradi M
    Methods Mol Biol; 2015; 1331():159-71. PubMed ID: 26169740
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potential targets for next generation antimicrobial glycoconjugate vaccines.
    Micoli F; Costantino P; Adamo R
    FEMS Microbiol Rev; 2018 May; 42(3):388-423. PubMed ID: 29547971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gold nanoparticles as carriers for a synthetic Streptococcus pneumoniae type 14 conjugate vaccine.
    Safari D; Marradi M; Chiodo F; Th Dekker HA; Shan Y; Adamo R; Oscarson S; Rijkers GT; Lahmann M; Kamerling JP; Penadés S; Snippe H
    Nanomedicine (Lond); 2012 May; 7(5):651-62. PubMed ID: 22630149
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antimicrobial glycoconjugate vaccines: an overview of classic and modern approaches for protein modification.
    Berti F; Adamo R
    Chem Soc Rev; 2018 Dec; 47(24):9015-9025. PubMed ID: 30277489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.